In a word, yes.
Part of the challenge we face is that it's really hard in the current system, because of the patchwork that exists, to ensure that this occurs across the board and that therefore there is some level of fairness, and also that we're taking advantage of the kinds of opportunities Dr. Tamblyn highlighted to continue to evaluate and therefore make really informed decisions. In cases in which the evidence shows that over time a drug is not nearly as effective as perhaps Health Canada or the formulary thought, or is not as safe as we thought, or is being used on an off-label basis too much and therefore we need to end that kind of decision making, there might be instances in which coverage is withdrawn, yes.